Lv1
98 积分 2025-10-12 加入
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
25天前
已完结
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
1个月前
已完结
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
3个月前
已完结
JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials
3个月前
已关闭
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy
3个月前
已完结
NCOG-37. Outcomes from online education focused on novel targeted therapies for IDH-mutant gliomas
4个月前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
4个月前
已完结
Oral Etoposide (VP16) in Platinum-Resistant Epithelial Ovarian Cancer (EOC)
4个月前
已完结
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
5个月前
已完结
皖公网安备34019202002308
